GSK’s Blenrep Receives FDA Approval for Relapsed/Refractory Multiple Myeloma
GSK’s Blenrep (belantamab mafodotin) receives FDA approval for relapsed/refractory multiple myeloma based on 51% death risk reduction in DREAMM-7 trial. Read the full details.